Document Detail


Acromegalic features in growth hormone (GH)-deficient patients after long-term GH therapy.
MedLine Citation:
PMID:  14974923     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Craniofacial, hand, foot and somatic growth depend on normal GH secretion. Acromegalic features have been described in children with GH insensitivity after IGF-I treatment. We observed patients with acromegalic features such as increase of foot size, nose and jaw enlargement among our cases with GH deficiency, treated with standard recombinant (rh)GH doses. The aim of our study was to analyse the possible factors involved in the development of acromegalic features in these patients. PATIENTS: We evaluated 21 patients, 17 with combined pituitary hormone deficiency and four with isolated GH deficiency treated with rhGH (0.05-0.15 U/kg/day, sc, at night) for 2-12 years who achieved final height. IGF-I and IGFBP-3 were measured before and every 6 months during therapy and bone age was evaluated yearly. At the end of therapy, patients' hand and foot sizes and height were measured and plotted on nomograms for hand according to height and age, and foot size according to height. Lateral radiographs of the face were performed to obtain the linear measurement of the lower jaw length. RESULTS: Foot size was greater than 97th percentile in 8/21 patients and lower jaw length was greater than +2SD in 4/21 patients. Patients were classified in two groups: group 1 (with foot size greater than 97th percentile and/or lower jaw length greater than +2SD) consisted of 11 patients (six females); nine had combined pituitary hormone deficiency (six associated to hypogonadotrophic hypogonadism) and three had isolated GH deficiency; group 2 (with foot size smaller than 97th percentile and lower jaw length less than +2SD) consisted of 10 patients (seven boys); nine had combined pituitary hormone deficiency (six associated to hypogonadotrophic hypogonadism) and one with isolated GH deficiency. During treatment, IGF-I levels ranged from < or = 3 to +2SD and IGFBP-3 levels ranged from -3 to +2SD, in both groups. We observed no statistically significant differences between the two groups regarding chronological age, bone age, height at the beginning and at the end of therapy, pubertal development, duration of rhGH treatment and IGF-I and IGFBP-3 levels (P > 0.05). Foot size percentile exceeded final height percentile in 11/21 patients (seven girls). CONCLUSION: Long-term rhGH treatment with standard doses might be associated with acromegalic features (increased foot size and lower jaw measurements) in patients with GH deficiency who achieved final height, especially in girls. Neither the clinical nor the hormonal parameters, IGF-I and IGFBP-3 levels, were useful to predict the development of these features. Further studies are necessary to analyse the frequency of this side-effect and how to prevent it.
Authors:
Luciani R Carvalho; Maria Estela Justamante de Faria; Maria Geralda Farah Osorio; Vivian Estefan; Alexander Augusto Lima Jorge; Ivo Jorge Prado Arnhold; Berenice Bilharinho Mendonca
Related Documents :
3653413 - Prolactin secretion and menstrual function after long-term bromocriptine treatment.
18196333 - Percutaneous treatment of pyocystis in patients with autosomal dominant polycystic kidn...
24263393 - Reconstitution of the nasal dorsum following component dorsal reduction in primary rhin...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  59     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2004-02-25     Completed Date:  2004-03-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  788-92     Citation Subset:  IM    
Affiliation:
Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormonios e Genetica Molecular LIM/42, Disciplina de Endocrinologia, HCFMUSP, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / blood,  chemically induced*,  diagnosis
Adolescent
Anthropometry
Child
Dwarfism, Pituitary / blood,  complications,  drug therapy*
Female
Foot Diseases / pathology
Human Growth Hormone / adverse effects,  therapeutic use*
Humans
Insulin-Like Growth Factor Binding Protein 3 / blood
Insulin-Like Growth Factor I / analysis
Male
Pituitary Hormones / deficiency
Time Factors
Chemical
Reg. No./Substance:
0/Insulin-Like Growth Factor Binding Protein 3; 0/Pituitary Hormones; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  GH treatment and its effect on bone mineral density, bone maturation and growth in short children bo...
Next Document:  Octreoscan in patients with bronchial carcinoid tumours.